Should the number of acute exacerbations in the previous year be used to guide treatments in COPD?

Sadatsafavi, Mohsen; McCormack, James; Petkau, John; Lynd, Larry D; Lee, Tae Yoon; Sin, Don D

Sadatsafavi, Mohsen; McCormack, James; Petkau, John; Lynd, Larry D; Lee, Tae Yoon; Sin, Don D.

Afiliação

Sadatsafavi M; Respiratory Evaluation Sciences Program, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada.
McCormack J; Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada.
Petkau J; UBC Centre for Heart Lung Innovation and Dept of Medicine (Respirology), University of British Columbia, Vancouver, BC, Canada.
Lynd LD; Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada.
Lee TY; Dept of Statistics, University of British Columbia, Vancouver, BC, Canada.
Sin DD; Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada.

Eur Respir J ; 57(2)2021 02.

Article em En | MEDLINE | ID: mdl-32855228

Assuntos

Doença Pulmonar Obstrutiva Crônica; Teorema de Bayes; Biomarcadores; Progressão da Doença; Humanos; Fenótipo; Doença Pulmonar Obstrutiva Crônica/terapia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença Pulmonar Obstrutiva Crônica Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Revista: Eur Respir J Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Canadá

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google